TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28948295

Group type: EXPERIMENTAL
Intervention: Routine chest and abdominopelvic CT-scan
Number of subjects: 140

Group type: COMPARATOR
Intervention: Selective CT-scan according to clinical presentation
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Routine chest CT-scan
Number of subjects: 140
Study: 26400648

Group type: EXPERIMENTAL
Intervention: Relevant movement condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Irrelevant movement condition
Number of subjects: 0
Study: 24628007

Group type: EXPERIMENTAL
Intervention: Gestational diabetes group
Number of subjects: 17

Group type: COMPARATOR
Intervention: Normal glucose tolerance group
Number of subjects: 17
Study: 23544125

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg/d
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg/d
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg/d plus Ezetimibe 10 mg/d
Number of subjects: 72
Study: 20598634

Group type: EXPERIMENTAL
Intervention: Screening group invited for PSA testing every 2 years (n=10,000)
Number of subjects: 19904

Group type: COMPARATOR
Intervention: Control group not invited for screening (n=10,000)
Number of subjects: 19904

Group type: EXPERIMENTAL
Intervention: Attendees of the screening group
Number of subjects: 19904

Group type: EXPERIMENTAL
Intervention: Overall screening invitation
Number of subjects: 19904
Study: 18194486

Group type: EXPERIMENTAL
Intervention: Somatostatin analogues
Number of subjects: 18
Study: 16539561

Group type: EXPERIMENTAL
Intervention: Low-speed tungsten-carbide bur (TCB)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: High-speed TCB
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Sof-Lex finishing disks
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Microetcher
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (group 4)
Number of subjects: 80
Study: 14615636

Group type: EXPERIMENTAL
Intervention: Corticosteroids (standard treatment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adjunctive agents (new treatments)
Number of subjects: 0
Study: 10636509

Group type: EXPERIMENTAL
Intervention: Oral contraceptive (OC) therapy
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT)
Number of subjects: 80
Study: 8959160

Group type: EXPERIMENTAL
Intervention: Morphine sulfate (MS)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 75
Study: 1550011

Group type: EXPERIMENTAL
Intervention: Low-cholesterol, low-fat, vegetarian diet, stress management, and moderate aerobic exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 3998921

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study: 30710614

Group type: EXPERIMENTAL
Intervention: Near-Infrared Light (NIRL)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Traditional Overhead White Light (WL)
Number of subjects: 170
Study: 30307901

Group type: EXPERIMENTAL
Intervention: Offset Analgesia (OA)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control Heat Stimulus (CTL)
Number of subjects: 17
Study: 26811529

Group type: EXPERIMENTAL
Intervention: Oxaliplatin added to FU + LV
Number of subjects: 12233

Group type: COMPARATOR
Intervention: FU + LV alone
Number of subjects: 12233

Group type: EXPERIMENTAL
Intervention: Both treatments (Oxaliplatin and FU + LV)
Number of subjects: 12233
Study: 24509454

Group type: EXPERIMENTAL
Intervention: Bioabsorbable staple line reinforcement
Number of subjects: 258

Group type: COMPARATOR
Intervention: No bioabsorbable staple line reinforcement
Number of subjects: 258

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 258
Study: 21834731

Group type: EXPERIMENTAL
Intervention: MDR website
Number of subjects: 56

Group type: COMPARATOR
Intervention: Information-only website
Number of subjects: 56

Group type: COMPARATOR
Intervention: Usual care condition
Number of subjects: 56
Study: 20357251

Group type: EXPERIMENTAL
Intervention: Filarial infections (Fil(+))
Number of subjects: 0

Group type: COMPARATOR
Intervention: Uninfected individuals (Fil(-))
Number of subjects: 0
Study: 17319331

Group type: EXPERIMENTAL
Intervention: College Alc (3-hour noncredit version)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 15321815

Group type: COMPARATOR
Intervention: 10 mg Zn (Zn group)
Number of subjects: 680

Group type: COMPARATOR
Intervention: 10 mg Fe (Fe group)
Number of subjects: 680

Group type: COMPARATOR
Intervention: 10 mg Fe and 10 mg Zn (Fe+Zn group)
Number of subjects: 680

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 680
Study: 11260566

Group type: EXPERIMENTAL
Intervention: Cefepime (CFP)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Ceftazidime (CFZ)
Number of subjects: 33
Study: 9843082

Group type: EXPERIMENTAL
Intervention: Ultrahigh-dose methylcobalamin (25 mg/day, intramuscularly, for 14 days)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Low-dose methylcobalamin (0.5 mg/day, intramuscularly, for 14 days)
Number of subjects: 24
Study: 7853070

Group type: EXPERIMENTAL
Intervention: Quick Medical Reference (QMR)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Textbooks without QMR
Number of subjects: 16
Study: 2666251

Group type: EXPERIMENTAL
Intervention: Hemoccult test with rehydration of slides
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hemoccult test
Number of subjects: 0
Study: 22515

Group type: EXPERIMENTAL
Intervention: Pipothiazine palmitate (100 mg, injected every 4th week)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Fluphenazine decanoate (25 or 37.5 mg, injected every 3rd week)
Number of subjects: 61
Study: 31934897

Group type: EXPERIMENTAL
Intervention: Tenapanor 50 mg b.i.d.
Number of subjects: 629

Group type: COMPARATOR
Intervention: Placebo b.i.d.
Number of subjects: 629
Study: 31136834

Group type: EXPERIMENTAL
Intervention: Guideline-based care (GBC) + referral to Psychologically Informed Physical Therapy (PIPT)
Number of subjects: 1860

Group type: COMPARATOR
Intervention: Guideline-based care (GBC)
Number of subjects: 1860

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 1860
Study: 28272748

Group type: EXPERIMENTAL
Intervention: Sevoflurane with 60% nitrous oxide in oxygen mixture
Number of subjects: 77

Group type: COMPARATOR
Intervention: Sevoflurane with 40% oxygen in air (control group)
Number of subjects: 77
Study: 25366931

Group type: EXPERIMENTAL
Intervention: Communities That Care (CTC)
Number of subjects: 4407

Group type: COMPARATOR
Intervention: Control
Number of subjects: 4407
Study: 23497371

Group type: EXPERIMENTAL
Intervention: Extended anticoagulation treatment (continuing warfarin treatment for a further 2 years)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine anticoagulation treatment (discontinuing warfarin treatment after 3-6 months)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: D-dimer levels measured using Roche Cobas h 232 POC device
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Villalta scale for signs and symptoms of post-thrombotic syndrome (PTS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: VEINES and EQ5D quality of life questionnaires
Number of subjects: 0
Study: 21086242

Group type: EXPERIMENTAL
Intervention: Resistance exercise (12 weeks, 3 days/week, 10 whole body resistance exercises, 3 sets at 8-RM)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Resistance exercise
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control
Number of subjects: 21
Study: 19050389

Group type: EXPERIMENTAL
Intervention: Atazanavir with ritonavir
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Atazanavir without ritonavir
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 117
Study: 16965776

Group type: COMPARATOR
Intervention: Simvastatin 20 mg and placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg and ramipril 10 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ramipril 10 mg and placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Combined therapy (simvastatin 20 mg and ramipril 10 mg)
Number of subjects: 50
Study: 15717477

Group type: EXPERIMENTAL
Intervention: Measles vaccination
Number of subjects: 5000

Group type: EXPERIMENTAL
Intervention: Oral polio vaccine (OPV) first dose
Number of subjects: 5000

Group type: EXPERIMENTAL
Intervention: Oral polio vaccine (OPV) second dose
Number of subjects: 5000
Study: 11911558

Group type: EXPERIMENTAL
Intervention: Tramadol/acetaminophen (37.5 mg/325 mg) tablets QID for 10 days
Number of subjects: 308

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Tramadol/acetaminophen
Number of subjects: 308
Study: 10414461

Group type: EXPERIMENTAL
Intervention: Neuronal autoantibodies in patients with limited SCLC (12/29 or 41% positive)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Neuronal autoantibodies of nuclear or cytoplasmic specificity in limited SCLC
Number of subjects: 58

Group type: COMPARATOR
Intervention: Neuronal autoantibodies and peripheral neuropathy
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Neuronal autoantibody titers during chemotherapy
Number of subjects: 58

Group type: COMPARATOR
Intervention: Seropositivity for neuronal autoantibodies and survival
Number of subjects: 58
Study: 7672496

Group type: EXPERIMENTAL
Intervention: GLP-1 [7-36 amide] 0.15 nmol/kg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: GLP-1 [7-36 amide] 0.5 nmol/kg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: GLP-1 [7-36 amide] 1.5 nmol/kg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: GLP-1 [7-36 amide] 4.5 nmol/kg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl with 1% human serum albumin)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: GLP-1 [7-36 amide] (all doses) after glucose stimulation
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: GLP-1 [7-36 amide] (all doses)
Number of subjects: 8
Study: 1983712

Group type: EXPERIMENTAL
Intervention: Niperotidine (460 mg administered at 22.00)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 379689

Group type: EXPERIMENTAL
Intervention: Apomorphine
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Physostigmine
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Levodopa
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 5
Study: 30287050

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass
Number of subjects: 63

Group type: COMPARATOR
Intervention: Intensive lifestyle modification and medical management protocol
Number of subjects: 63
Study: 28222101

Group type: EXPERIMENTAL
Intervention: Join the Healthy Boat health promotion program
Number of subjects: 1733

Group type: COMPARATOR
Intervention: Control group (wait-list)
Number of subjects: 1733
Study: 25833816

Group type: EXPERIMENTAL
Intervention: Pressure Pain Sensitivity (PPS) during Tilt Table Test (TTT)
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Reduction in resting PPS after stress intervention
Number of subjects: 361
Study: 23924233

Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate (FF) 100 μg
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Vilanterol (VI) 25 μg
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate and Vilanterol (FF/VI) 100/25 μg
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 21350242

Group type: EXPERIMENTAL
Intervention: HRA-O program with personal reinforcement (group sessions or home visits)
Number of subjects: 878

Group type: COMPARATOR
Intervention: Control group (no personal reinforcement)
Number of subjects: 878

Group type: COMPARATOR
Intervention: Comparison group (physician training alone)
Number of subjects: 878
Study: 19493864

Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT)
Number of subjects: 813

Group type: COMPARATOR
Intervention: Control group (no CRT)
Number of subjects: 813
Study: 18257343

Group type: EXPERIMENTAL
Intervention: Ginger-partitioned moxibustion
Number of subjects: 221

Group type: COMPARATOR
Intervention: Oral administration of Chinese patent medicine
Number of subjects: 221
Study: 15312215

Group type: EXPERIMENTAL
Intervention: N-acetyl-L-cystein (NAC) infusion (150 mg/kg bolus followed by 12.5 mg/kg/hour for 6 hours)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Dextrose (5% solution) administered at the same dosage as NAC
Number of subjects: 53
Study: 11468553

Group type: EXPERIMENTAL
Intervention: Sirolimus and prednisone (with or without cyclosporine)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Azathioprine/mycophenolate and prednisone with cyclosporine
Number of subjects: 22
Study: 9542480

Group type: EXPERIMENTAL
Intervention: Avitriptan (150 mg doses, 2 hours apart)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propranolol (80 mg twice a day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Avitriptan alone
Number of subjects: 0
Study: 7992348

Group type: EXPERIMENTAL
Intervention: 500 mg mebendazole
Number of subjects: 2294

Group type: COMPARATOR
Intervention: 400 mg albendazole
Number of subjects: 2294

Group type: EXPERIMENTAL
Intervention: 500 mg mebendazole (Janssen)
Number of subjects: 2294

Group type: COMPARATOR
Intervention: 500 mg mebendazole (Pharmamed)
Number of subjects: 2294
Study: 2730505

Group type: EXPERIMENTAL
Intervention: guided mastery treatment based on self‐efficacy theory
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: stimulus exposure treatment
Number of subjects: 26

Group type: COMPARATOR
Intervention: delayed treatment
Number of subjects: 26
Study: 805675

Group type: EXPERIMENTAL
Intervention: Propranolol 160 mg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Propranolol 320 mg
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 31274786

Group type: EXPERIMENTAL
Intervention: Scenario plus video
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Scenario
Number of subjects: 36
Study: 28380495

Group type: COMPARATOR
Intervention: Double-blind placebo-controlled food challenge (OFC)
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: History of anaphylaxis to the causative food
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Older age (per 1 year increase)
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Egg OFC
Number of subjects: 393
Study: 26246322

Group type: EXPERIMENTAL
Intervention: Total Protein Intake (TPro) ≥1.0 to <1.2 g · kg(‐1) · d(‐1)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Total Protein Intake (TPro) ≥1.2 g · kg(‐1) · d(‐1)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Total Protein Intake (TPro) <1.0 g · kg(‐1) · d(‐1)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Change in Total Protein Intake (CTPro)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Metabolic Syndrome Indexes
Number of subjects: 117
Study: 23849104

Group type: EXPERIMENTAL
Intervention: Uninterrupted OAC (N=106)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Interrupted OAC (N=107)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 213
Study: 20390281

Group type: EXPERIMENTAL
Intervention: Mud‐bath therapy with mineral water from the Sillene Spring at Chianciano Spa
Number of subjects: 61
Study: 19901194

Group type: EXPERIMENTAL
Intervention: Mean heart rate <75 bpm
Number of subjects: 1530

Group type: EXPERIMENTAL
Intervention: Mean heart rate >90 bpm
Number of subjects: 1530

Group type: EXPERIMENTAL
Intervention: Mean heart rate as a continuous variable
Number of subjects: 1530
Study: 16603829

Group type: EXPERIMENTAL
Intervention: Lipid-lowering agents
Number of subjects: 0
Study: 14738231

Group type: EXPERIMENTAL
Intervention: Immediate polysomnography (group 1)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Polysomnography within 6 months (group 2)
Number of subjects: 171
Study: 11765592

Group type: EXPERIMENTAL
Intervention: Cetirizine hydrochloride 5 mg and pseudoephedrine hydrochloride 120 mg (CTZ/PSE)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Xylometazoline hydrochloride 0.1% (XMZ)
Number of subjects: 36
Study: 9212355

Group type: EXPERIMENTAL
Intervention: Low Molecular Weight Heparin (LMWH)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 22
Study: 7870932

Group type: EXPERIMENTAL
Intervention: Cocaine and ethanol administration
Number of subjects: 6

Group type: COMPARATOR
Intervention: Cocaine administration
Number of subjects: 6

Group type: COMPARATOR
Intervention: Ethanol administration
Number of subjects: 6
Study: 3759500

Group type: EXPERIMENTAL
Intervention: Keeping a diet diary (self‐monitoring)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Receiving leaflets describing and recommending cue avoidance
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Being seen in a group
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 160
Study: 30518331

Group type: EXPERIMENTAL
Intervention: Td + PCV13
Number of subjects: 448

Group type: COMPARATOR
Intervention: Td alone
Number of subjects: 448

Group type: COMPARATOR
Intervention: PCV13 alone
Number of subjects: 448
Study: 27028499

Group type: EXPERIMENTAL
Intervention: HIV positive women who did not disclose their status to their partner
Number of subjects: 1092

Group type: EXPERIMENTAL
Intervention: HIV positive women who disclosed their status to their partner
Number of subjects: 1092

Group type: COMPARATOR
Intervention: HIV negative women
Number of subjects: 1092
Study: 24927299

Group type: EXPERIMENTAL
Intervention: IT-based intervention (ManUp)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Print-based intervention
Number of subjects: 301
Study: 22401331

Group type: EXPERIMENTAL
Intervention: Optimized data entry method
Number of subjects: 40

Group type: COMPARATOR
Intervention: Initial data entry methods
Number of subjects: 40
Study: 20721962

Group type: EXPERIMENTAL
Intervention: Injection of activated carbon nanoparticles
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Injection of methylene blue
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no tracer)
Number of subjects: 60
Study: 18287790

Group type: EXPERIMENTAL
Intervention: Dentin with 5,000 ppm F, NaF, silica (D)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Dentin with 1,100 ppm F, NaF, silica (C)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo dentifrice with 22 ppm F, silica
Number of subjects: 10
Study: 15625254

Group type: EXPERIMENTAL
Intervention: Xenon (70%)
Number of subjects: 30

Group type: COMPARATOR
Intervention: N(2)O (70%) and desflurane (2%)
Number of subjects: 30
Study: 12660266

Group type: EXPERIMENTAL
Intervention: 1200 mg testosterone implant plus daily oral placebo
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: 1200 mg testosterone plus oral Q 75 microg/day
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: 800 mg testosterone plus oral Q 75 microg/day
Number of subjects: 46
Study: 11766652

Group type: EXPERIMENTAL
Intervention: Minimal osteosynthesis in elderly patients with dislocated two-part fractures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: T-plate fixation in younger patients with dislocated two-part fractures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Minimally invasive techniques for three- and four-part fractures in elderly patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alternative therapies such as conservative treatment and plating
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Primary implantation of a prosthesis in four-part fractures in the elderly
Number of subjects: 0
Study: 9499783

Group type: EXPERIMENTAL
Intervention: Subjective review of corneal topography
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Relative scale
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Absolute scale
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Experienced reviewers
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Inexperienced reviewers
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Alcon device
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Eyesys device
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Tomey device
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Low myopia (−1.50 to −2.99 D)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Medium myopia (−3.00 to −4.49 D)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: High myopia (−4.50 to −6.00 D)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Homogeneous topographic pattern
Number of subjects: 38
Study: 7877826

Group type: EXPERIMENTAL
Intervention: 131I-HIPDM injection
Number of subjects: 35
Study: 3374026

Group type: EXPERIMENTAL
Intervention: Benzbromarone (non-micronised brands)
Number of subjects: 10
Study: 31800798

Group type: EXPERIMENTAL
Intervention: Home visits by nurses after hospital discharge (Intervention Group)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Conventional follow-up in conventional health services (Control Group)
Number of subjects: 44
Study: 31132997

Group type: EXPERIMENTAL
Intervention: CHW
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CHW + CCT
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control
Number of subjects: 12
Study: 28292763

Group type: EXPERIMENTAL
Intervention: Dynamic plantar flexion exercise at 40% of the maximal work rate (WRmax)
Number of subjects: 24
Study: 26335334

Group type: EXPERIMENTAL
Intervention: Relaxation prestripping
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Relaxation poststripping
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control (no relaxation)
Number of subjects: 121
Study: 23605600

Group type: EXPERIMENTAL
Intervention: Acupressure using a wrist elastic band on the Nei‐Guan acupuncture point, applied 30 minutes prior to spinal anesthesia.
Number of subjects: 152

Group type: COMPARATOR
Intervention: Control group (no acupressure intervention).
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Acupressure group.
Number of subjects: 152
Study: 22026323

Group type: EXPERIMENTAL
Intervention: Parent-delivered Qigong massage program for 4 months
Number of subjects: 47
Study: 19113926

Group type: EXPERIMENTAL
Intervention: Daily teriparatide for 15 months
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Cyclic teriparatide for 15 months
Number of subjects: 32

Group type: COMPARATOR
Intervention: Alendronate alone for 15 months (control group)
Number of subjects: 32